Table 2.
Variables | Total N=92 |
PLR median group | OR (95% CI) | p-value | |
---|---|---|---|---|---|
High (≥108) n=46 |
Low (<108) n=46 |
||||
In Hospital outcome | |||||
Acute lung oedema, n (%) | 37 (40.2) | 23 (50.0) | 14 (30.4) | 1.39 (0.98–1.96) | 0.058 |
Cardiogenic Shock, n (%) | 12 (13.04) | 6 (13.0) | 6 (13.0) | 1.00 (0.85–1.17) | 1.000 |
Life threatening arrhythmia, n (%) | 14 (15.38) | 9 (19.6) | 5 (10.9) | 1.11 (0.93–1.32) | 0.384 |
Length of stay, median [IQR] | 4 [4–6] | 4 [4–5] | 4 [4–6] | 1.00 (0.99–1.04) | 0.893 |
Long term outcome | |||||
First HF symptom during 6-month follow up (NYHA class II–IV) (%) | 65 (70.65) | 41 (89.13) | 24 (52.17) | 1.70 (1.33–2.18) | <0.001 |
MACE during 6-month follow up | 10 (10.86) | 4 (8.69) | 6 (13.04) | 0.67 (0.24–1.41) | 0.738 |
HF – heart failure; IQR – interquartile range; PLR – platelet-to-lymphocyte ratio; MACE – major adverse cardiac events; OR – odds ratio; PLR – platelet-to-lymphocyte ratio; NYHA – New York Heart Association. P value <0.05 was considered statistically significant.